Get the Stockscreener App
28.85
3.81%
1.06
Rapt Therapeutics Inc stock is traded at $28.85, with a volume of 283.14K.
It is up +3.81% in the last 24 hours and up +15.40% over the past month.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.
See More
Previous Close:
$27.79
Open:
$26.97
24h Volume:
283.14K
Relative Volume:
0.75
Market Cap:
$477.12M
Revenue:
$3.25M
Net Income/Loss:
$-116.80M
P/E Ratio:
-9.459
EPS:
-3.05
Net Cash Flow:
$-98.17M
1W Performance:
-0.03%
1M Performance:
+15.40%
6M Performance:
+380.71%
1Y Performance:
+181.74%
1-Day Range:
$26.78
$29.27
1-Week Range:
$26.78
$30.12
52-Week Range:
$5.6652
$42.39
Rapt Therapeutics Inc Stock (RAPT) Company Profile
Name
Rapt Therapeutics Inc
Sector
Industry
Phone
(650) 489-9000
Address
561 ECCLES AVENUE, SOUTH SAN FRANCISCO, CA
Compare RAPT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RAPT
Rapt Therapeutics Inc
|
28.85 | 770.09M | 3.25M | -116.80M | -98.17M | -3.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
437.15 | 110.25B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
693.50 | 73.04B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
449.16 | 59.98B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
907.98 | 54.90B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
193.22 | 40.73B | 447.02M | -1.18B | -906.14M | -6.1812 |
Rapt Therapeutics Inc Stock (RAPT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-27-25 | Initiated | Guggenheim | Buy |
| Oct-20-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-13-25 | Initiated | Barclays | Overweight |
| Sep-26-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jul-30-25 | Upgrade | JP Morgan | Underweight → Neutral |
| May-22-25 | Resumed | H.C. Wainwright | Buy |
| Dec-26-24 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Nov-13-24 | Downgrade | Stifel | Buy → Hold |
| Nov-11-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-11-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| May-14-24 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| May-10-24 | Downgrade | Barclays | Overweight → Equal Weight |
| May-10-24 | Downgrade | Guggenheim | Buy → Neutral |
| Feb-22-24 | Downgrade | UBS | Buy → Neutral |
| Feb-21-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Feb-21-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-21-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Feb-20-24 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-16-24 | Initiated | Evercore ISI | Outperform |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Sep-14-23 | Initiated | Berenberg | Buy |
| Aug-09-23 | Initiated | Stifel | Buy |
| Jun-15-23 | Initiated | Barclays | Overweight |
| Jan-04-23 | Initiated | Guggenheim | Buy |
| Dec-01-22 | Initiated | Goldman | Buy |
| Sep-21-22 | Initiated | CapitalOne | Overweight |
| May-24-22 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-09-21 | Initiated | JP Morgan | Overweight |
| Aug-12-21 | Initiated | SVB Leerink | Outperform |
| Jun-21-21 | Initiated | Piper Sandler | Overweight |
| Jun-01-20 | Initiated | H.C. Wainwright | Buy |
| May-19-20 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-13-20 | Initiated | ROTH Capital | Buy |
| Nov-25-19 | Initiated | BMO Capital Markets | Outperform |
| Nov-25-19 | Initiated | UBS | Buy |
| Nov-25-19 | Initiated | Wells Fargo | Outperform |
View All
Rapt Therapeutics Inc Stock (RAPT) Latest News
What to expect from RAPT Therapeutics Inc. in the next 30 daysJuly 2025 Retail & Safe Swing Trade Setups - newser.com
Why RAPT Therapeutics Inc. stock appeals to dividend seekersPortfolio Return Report & Free Accurate Trade Setup Notifications - newser.com
How RAPT Therapeutics Inc. (0RA0) stock stacks up against competitorsProfit Target & Fast Exit/Entry Strategy Plans - newser.com
Is RAPT Therapeutics Inc. stock reversal real or fakeJuly 2025 Price Swings & Consistent Growth Equity Picks - newser.com
RAPT Therapeutics Inc. recovery potential after sell offJuly 2025 Trends & Free Low Drawdown Momentum Trade Ideas - newser.com
How RAPT Therapeutics Inc. stock benefits from tech adoptionWeekly Profit Report & Growth Focused Investment Plans - newser.com
Does RAPT Therapeutics Inc. (0RA) stock trade below intrinsic value2025 Retail Activity & Fast Exit Strategy with Risk Control - newser.com
Can RAPT Therapeutics Inc. recover in the next quarterMarket Volume Summary & Safe Capital Growth Trade Ideas - newser.com
Why RAPT Therapeutics Inc. (0RA) stock is trending on social mediaQuarterly Trade Report & AI Forecasted Entry and Exit Points - newser.com
Why retail investors favor RAPT Therapeutics Inc. stock2025 Price Momentum & Advanced Technical Signal Analysis - newser.com
Can RAPT Therapeutics Inc. (0RA) stock attract ESG investments2025 Institutional Moves & Weekly Breakout Watchlists - newser.com
Can RAPT Therapeutics Inc. (0RA) stock resist broad market declinesEarnings Recap Report & AI Based Buy and Sell Signals - newser.com
What to do if you’re stuck in RAPT Therapeutics Inc.July 2025 Sentiment & AI Driven Stock Price Forecasts - newser.com
Technical signs of recovery in RAPT Therapeutics Inc.Fed Meeting & Daily Chart Pattern Signal Reports - newser.com
How institutional buying supports RAPT Therapeutics Inc. stock2025 Winners & Losers & Technical Pattern Based Buy Signals - newser.com
What macro factors could drive RAPT Therapeutics Inc. (0RA0) stock higherJuly 2025 Intraday Action & Short-Term Trading Alerts - newser.com
Can RAPT Therapeutics Inc. stock outperform in 2025 bull marketMarket Movers & Accurate Buy Signal Notifications - newser.com
RAPT Therapeutics: Strong Promise In Immunology, Looks Like An Opportunity At These Prices - Seeking Alpha
Can RAPT Therapeutics Inc. (0RA) stock survive global slowdownJuly 2025 WrapUp & Risk Adjusted Swing Trade Ideas - newser.com
Can RAPT Therapeutics Inc. (0RA) stock ride next bull market cycle2025 Winners & Losers & Safe Entry Momentum Tips - newser.com
Will RAPT Therapeutics Inc. (0RA) stock beat revenue estimatesJuly 2025 Fed Impact & Verified Entry Point Signals - Fundação Cultural do Pará
Will RAPT Therapeutics Inc. (0RA0) stock outperform value peers2025 Trading Volume Trends & Weekly High Potential Alerts - newser.com
Can RAPT Therapeutics Inc. (0RA0) stock sustain margin levelsChart Signals & High Win Rate Trade Tips - newser.com
Is RAPT Therapeutics Inc. (0RA0) stock a buy before earnings resultsJuly 2025 Sentiment & Accurate Technical Buy Alerts - newser.com
Rapt Therapeutics Inc Stock (RAPT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.43%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):